Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wipe could stop armpit sweat in its tracks

NCT ID NCT02129660

Symptom relief Sponsor: Journey Medical Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested two different medicated wipes (glycopyrrolate and glycopyrronium) against a placebo wipe for people with excessive underarm sweating. 105 adults used the wipes once daily for 4 weeks, then stopped for 2 weeks. Researchers measured sweat production and how much sweating affected daily life to see if the wipes helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glycopyrrolate and glycopyrronium topical wipes
What this could lead to
If successful, this could lead to a new prescription wipe that reduces excessive underarm sweating with daily use.
What could go wrong
This is an early Phase 2 trial with only 105 people, so results may not apply to everyone. The treatment is for symptom control, not a cure, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

105 people

The number who actually took part.

Start date

Apr 2014

Finished

Jan 2015

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 18 years of age or older. * Primary, axillary hyperhidrosis of at least 6 months duration. * Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline. * For each axilla, a baseline gravimetric measurement of sweat production of at least 50 mg over 5 minutes, while at rest, at room temperature. * Male or non-pregnant, non-lactating females. Exclusion Criteria: * Current pregnancy or lactation. * Prior surgical procedure for hyperhidrosis. * Any prior axillary treatment with an anti-hyperhidrosis medical device * Any prior treatment with an investigational drug within 4 weeks prior to Baseline/Day 1 or within 5 elimination half lives of the active agent, whichever is longer or 6 weeks if the elimination half life is not known. Experimental devices are excluded without the approval of the Medical Monitor. * Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1. * Subjects with clinically significant abnormalities in laboratory values. * Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is allowed only if the subject has a history of having received Hepatitis B vaccination and there are no clinically significant abnormalities in screening liver function tests. * Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis, within one month prior to Baseline/Day 1. * Treatment with psychotherapeutic medications for less than 4 months prior to Baseline/Day 1. * Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks of the baseline visit * Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1. * Any previous IV or oral treatment with the study drug. * Prior treatment with the topical study drug in a previous trial. * Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment. * Presence of a condition, within 10 years of enrollment, that may cause secondary hyperhidrosis * Menopausal women who have had symptoms of menopause such as sweating or flushing within 3 years of the study may not be enrolled. * Known history of Sjögren's syndrome or Sicca syndrome. * History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness. * Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy. * Abnormal findings on screening ECG deemed clinically significant by the Investigator. * History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter. History of other supraventricular tachycardia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperhidrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperhidrosis hyperhidrosis palmaris ET plantaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperhidrosis

Contacts and locations

Locations

  • California Dermatology & Clinical Research Institute

    Encinitas, California, 92024, United States

  • Center For Dermatology Clinical Research

    Fremont, California, 94538, United States

  • DermResearch, Inc

    Austin, Texas, 78759, United States

  • Dermatology Associates

    Seattle, Washington, 98101, United States

  • Dermatology Research Center, Inc.

    Salt Lake City, Utah, 84117, United States

  • Haber Dermatology and Cosmetic Surgery

    Beachwood, Ohio, 44122, United States

  • Innovaderm Research Inc.

    Montreal, H2K 4L5, Canada

  • Kenneth R. Beer MD

    West Palm Beach, Florida, 33401, United States

  • Olympian Clinical Research

    Tampa, Florida, 33609, United States

  • Premier Clinical Research

    Spokane, Washington, 99204, United States

  • Rivergate Dermatology Clinical Research Center, PLLC

    Goodlettsville, Tennessee, 37072, United States

  • Saint Louis University Dermatology

    St Louis, Missouri, 63122, United States

  • Shideler Clinical Research Center

    Carmel, Indiana, 46032, United States

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia, 23507, United States

  • Women's Clinical Research Center

    Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.